Avenzo Therapeutics’ Post

📢 Another VC Firm Raises a Fresh Round of Capital! The seasoned team at Medicxi is making headlines once again, as they announce the launch of their impressive new $400M fund (Medicxi IV). 💼 With their proven track record and industry expertise, this veteran crew is set to make significant waves in the healthcare and life sciences sectors. The group's investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna (Phathom Pharmaceuticals) and obicetripib (NewAmsterdam Pharma). A number of Medicxi assets have been acquired by global pharmaceutical companies, including Villaris therapeutics (Incyte), MiroBio Ltd (Gilead Sciences), and Versanis Bio (Eli Lilly and Company) within the last twelve months. In a recent interview, Medicxi co-founder Francesco De Rubertis shared the firm's optimistic outlook on the future of the industry, underlining the groundbreaking advancements that lie ahead. Their upbeat assessment is undoubtedly infectious and has already garnered immense interest from investors and entrepreneurs alike. Read more about this exciting development here: https://lnkd.in/eCZC-bMA #biotech #healthcare #lifesciences #innovation #investments #Medicxi #funding #startups #transformation

What do biotech investors look for when considering a deal? Strong leadership, strategic foresight, financial efficiency, and deep industry knowledge are all key deciding factors. Curious to learn more? Gain invaluable insights on M&A advisory and investor decision-making from Bracken Managing Partner, James Gilligan, in this blog post: https://lnkd.in/eMzHrtpx #LifeSci #Biopharma #Investing #DueDiligence #Bracken

💹💰 It may be June, but the UK hasn't quite got the memo about the summer weather. So I'm back to warm you up with an impressive #financialfriday wrap up this week. The money keeps rolling in for the Biotech industry as we head towards the half year mark, so watch below for an overview of this weeks deals: 💵 Alzheon, Inc. | Preserving Future Memories $100 million series E 💳 Amber Therapeutics $100 million series A 💷 Bright Peak Therapeutics $90 million series C 💸 Prolific Machines, Inc. $55 million series B1 💲 Adcytherix €30 million seed funding #financialfriday #biotechinvestment #venturecapitalist #vcinvestment

Newcourt Acquisition in a proxy filing called a Jan. 18 meetign for shareholders to vote on the proposed business combination with Psyence Bioscience. The deal values Psyence Biomedical at a pre-money equity value of $50 million.  A subsidiary of Psyence Group, the Toronto-based target is a clinical-stage life science biotechnology company developing uses for nature-derived psilocybin in mental health and wellbeing. At deal announcement a year ago, terms called for Psyence to receive a minimum of $20 million cash held in trust. Newcourt raised $220 million in an October 2021 IPO, although the account is now down to approximately $12.8 million as of Jan. 9, according to the proxy. Currently, the Newcourt sponsor owns approximately 84.8% of the SPAC’s outstanding shares.  https://lnkd.in/d_fEGTRH

San Francisco-based Foresite Capital ,led by founder and CEO Jim Tananbaum has closed its sixth fund with $900 million in capital commitments, emphasizing its dedication to advancing healthcare and life sciences technologies. Fund VI has attracted a diverse group of global investors, reflecting strong confidence in Foresite Capital's strategy. The firm will focus on precision therapeutics, life science infrastructure, and healthcare delivery. Founded in 2011, Foresite Capital manages over $3.5 billion in assets and has a notable track record, including 47 IPOs and 58 FDA-approved drugs. The fund's portfolio features promising companies like Alumis and CG Oncology. #ForesiteCapital #HealthcareInvestment #LifeSciences #PrecisionTherapeutics #BiotechInnovation #InvestmentFund #HealthcareDelivery #VentureCapital #FundVI #BiotechInvesting #startup77

SPAC Feed: Denali Capital Acquisition Outlines Longevity Biomedical Deal with Investor Presentation - https://lnkd.in/eNr_ceqg Denali Capital Acquisition filed an investor presentation highlighting its proposed combination with Longevity Biomedical at a pro forma equity valuation of… #SPACs #SPACNews #SPAC #IPO #markets #news #capitalmarkets #trends #goingpublic

Where's the next Cubic Telecoms? Get to know the new EIIS rules and gain 50% investment discounts, see lots of great early stage stories all year, and start building your own fund at your own size and speed... with NO fees. For a systematic and professional approach this EIIS Private Portfolio explainer could be a big help for 2024.... https://lnkd.in/gq2zuCaC ATXA Therapeutics Altach (an NLC Venture)

WSB Investor Call | June 21, 2022 (Preview) Here's a preview of the investor call with David Maris and Sarepta Therapeutics CEO Douglas S. Ingram. Whether you own $SRPT or thinking of getting long, you can't miss this discussion. "Our goal here is to delve deeper into the implications of the approval and understand Sarepta's longer term objectives." - David Maris "This is an enormous moment for the company." - Doug Ingram Access the entire Investor Call on $SRPT and don't miss Doug's incredible insights near the end on the importance of corporate culture in his organizations. Click the link in the comments sections to access. Fantastic discussion gentlemen! #InvestSmarter

Thoughts on this? >> Alexis Borisy and Zach Weinberg's Curie.Bio secures $380M to support portfolio's Series A rounds >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #healthcare #biotech

Inspiring Science, Inspiring Teamwork, Inspiring Entrepreneurship @argenx . See below for the full interview with our CEO Tim Vanhauwermeiren.